Astrazeneca PLC (NYSE:AZN) was upgraded by stock analysts at Credit Suisse Group from a “neutral” rating to an “outperform” rating in a research note issued on Monday, October 16th, Marketbeat.com reports.
A number of other analysts have also commented on AZN. Barclays PLC reaffirmed an “overweight” rating on shares of Astrazeneca PLC in a research note on Monday, July 3rd. BidaskClub lowered Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. Zacks Investment Research lowered Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a research report on Monday, July 17th. Finally, Leerink Swann lowered Astrazeneca PLC from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $36.00 to $31.00 in a research report on Thursday, July 27th. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $35.10.
Shares of Astrazeneca PLC (NYSE AZN) opened at 33.49 on Monday. The stock’s 50 day moving average price is $33.66 and its 200-day moving average price is $32.47. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60. The company has a market cap of $84.80 billion, a PE ratio of 21.97 and a beta of 0.76.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter last year, the business earned $0.83 earnings per share. The business’s revenue was down 9.9% on a year-over-year basis. On average, equities research analysts forecast that Astrazeneca PLC will post $1.91 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/28/astrazeneca-plc-azn-raised-to-outperform-at-credit-suisse-group.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. purchased a new stake in shares of Astrazeneca PLC during the 2nd quarter worth approximately $105,000. Salem Investment Counselors Inc. purchased a new stake in shares of Astrazeneca PLC during the 1st quarter worth approximately $107,000. Tower Research Capital LLC TRC raised its holdings in shares of Astrazeneca PLC by 3,782.0% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after acquiring an additional 3,782 shares in the last quarter. WFG Advisors LP raised its holdings in shares of Astrazeneca PLC by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after acquiring an additional 984 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. raised its holdings in shares of Astrazeneca PLC by 71.2% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after acquiring an additional 1,769 shares in the last quarter. 14.18% of the stock is currently owned by institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.